Beta-Adrenergic Blockade in Chronic Heart Failure

Scandinavian Cardiovascular Journal

Volumn 32, Issue 47, 1998, Pages 45-55

  Bristow, Michael ^a   Port, J David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART MUSCLE; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; BETA ADRENERGIC RECEPTOR BLOCKING; CONFERENCE PAPER; HEART FAILURE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 0031613284     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/140174398428045     Document Type: Article

References (85)

1. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med 1984; 311: 850 – 851.
2. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol 1985; 55: D120–D124.
3. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. /3-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985; 17 (Suppl 2): 41 – 52.
4. Fowler MB, Bristow MR, Laser JA, Ginsburg R, Scott LB, Schroeder JS. /3-blocker therapy in severe heart failure: improvement related to #1-adrenergic receptor up regulation? Circulation 1984; 11 – 70: 446.
5. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and /3-adrenergic receptor density in failing human hearts. New Engl JoMed 1982; 307: 205 – 211.
6. Waagstein F, Hjalmarson A, Vamauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade incongestive cardiomyopathy. Br Heart J 1975; 37: 1022 – 1036.
7. Swedberg K, Waagstein F, Hjalmarson A, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; i: 1374 – 1376.
8. Swedberg KI, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in con-gestive cardiomyopathy. Br Heart J 1980; 44: 117 – 133.
9. Bristow MR, Ginsburg R, Fowler M, Minobe W, Rasmussen R, Zera P. et al. /31 and /32-adrenergic receptor subpopulations in normal and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective /31 receptor down-regulation in heart failure. Circ Res 1986; 59: 297 – 309.
10. Brodde OE, Schuler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, et al. Regional destricution of /3-adreno-ceptors in the human heart: coexistence of function 'gl-and /32 adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Phar-macol 1986; 8: 1235 – 1242.
11. Bohm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold, Erdmann E. Subsensitivity of the failing human heart to isoproterenol and milrinone is related to /3-adrenoceptor downregulation. J Cardiovasc Pharma-col 1988; 12: 726 – 732.
12. Bristow MR, Anderson FL, Port JD, Skerl L, Hersh-berger RE, Larrabee P. et al. Differences in /3-adrenergic neuroeffector mechanisms in ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991; 84: 1024 – 1039.
13. Anderson FL, Port JD, Reid BB, Larrabee P, Hanson G, Bristow MR. Myocardial catecholamine and neuropep-tide Y depletion in the failing ventricles of patients with idiopathic dilated cardiomyopathy: correlation with beta adrenergic down-regulation. Circulation 1992; 85: 46 – 53.
14. Bristow MR, Minobe W, Rasmussen R, Larrabee P. Skerl L, Klein JVV, et al. /3-adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. J Clin Invest 1992; 89: 803 – 815.
15. Bristow MR, Minobe W, Raynolds MV, Port JD, Rasmussen R, Ray PE, et al. Reduced /31 receptor mRNA abundance in the failing human heart. J Clin Invest 1993; 92: 2737 – 2745.
16. lingerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of, 6-adrenergic receptor kinase and, 61-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454 – 463.
17. Swedburg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without heart failure. Am J Cardiol 1984; 54: 783 – 786.
18. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with chronic congestive heart failure. Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73: 615 – 621.
19. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the, 6-adrenergic receptor pathway in the intact failing human heart: progressive, 6-receptor down-regulation and specific pharmacologic subsensi-tivity to agonist response. Circulation 1986; 74: 1290 – 1302.
20. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased, 6-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79: 483 – 490.
21. Waagstein F., Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A. Long-term /3-blockade in dilated cardio-myopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551 – 563.
22. White M, Yanowitz F, Gilbert EM, Larrabee P. O'Connell JB, Anderson JL, et al. Role of beta-adrenergic receptor downregulation in the peak exercise response of patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995; 76: 1271 – 1276.
23. Engelhardt S, Bohm M, Erdman E, Lohse MJ. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reaction: progressive reduction of, 61-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 1996; 27: 146 – 154.
24. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, De-Freyte G, et al. Effects of chronic, 6-adrenergic blockade on the left ventricular and cardiocyte abnorm-alities of chronic canine mitral regurgitation. J Clin Invest 1994; 93: 2639 – 2648.
25. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progres-sion of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994; 89: 2852 – 2859.
26. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994; 24: 1762 – 1768.
27. Reithmann C, Gierschik P. Sidiropoulos D, Werdan K, Jakobs KH. Mechanism of noradrenaline-induced het-erologous desensitization of adenylate cyclase stimula-tion in rat heart muscle cells: increase in the level of inhibitory G-protein a-subunits. Eur J Pharmacol 1989; 172: 211 – 221.
28. Mann DL, Kent RL, Parsons B, Cooper IV G. Adrenergic effects on the biology of the adult mamma-lian cardiocyte. Circulation 1992; 85: 790 – 804.
29. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsc, overexpres-sion. Circ Res 1996; 78: 517 – 524.
30. Bisognano JD, Pende A, Tremmel KD, Bohlmeyer TJ, Knudson O, Bristow MR, et al. Preliminary character-ization of a transgenic mouse overexpressing the human f31-adrenergic receptor. J Invest Med 1997; 45: 210A.
31. Bittner HB, Chen EP, Milano CA, Jennings RB, Letko-witz RJ, Van Trigt P. The effects of ischemia and age on myocardial function in human, 6-adrenergic receptor gene overexpressed hearts. Circulation 1995; 92: 1 – 233.
32. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, et al. Myocardial expression of a constitutively active o1-adrenergic receptor in trans-genic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994; 91: 10109 – 10113.
33. Kaye DM, Ketkovits J, Jennings GL, Bergin P. Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26: 1257 – 1263.
34. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997; 95: 169 – 175.
35. Bristow MR, Durham C, Kline J, Rasmussen R, Port JD, Gesteland RR, et al. Down-regulation of, 6-adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. Clin Res 1991; 39: 256A.
36. Gilbert EM, Sandoval A, Larrabee P. Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases, 6-receptor density in the failing human heart. Circulation 1993; 88: 472 – 480.
37. Hall JA, Kaumann AJ, Brown MJ. Selective, 61-adreno-ceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through /32-adre-noceptors in human atrial myocardium. Circ Res 1990; 66: 1610 – 1623.
38. Eichhom EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94: 2285 – 2296.
39. Imperato-McGinley F, Gautier T, Ehlers K, Zullo MA, Golstein DS, Vaughan Jr ED. Reversibility of catecho-lamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med 1987; 316: 793 – 797.
40. White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, et al. Cardiac, 6-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: evidence for catecholamine-mediated myocardial damage. Circulation 1995; 92: 2183 – 2189.
41. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J 1995; 16(Suppl F): 20 – 31.
42. Haber HL, Simek CL, Gimple LW, Bergin JD, Subbiah K, Jayaweera AR, et al. Why do patients with congestive heart failure tolerate the initiation of, 6-blocker therapy? Circulation 1993; 88: 1610 – 1619.
43. Lowes BD, Minobe WA, Abraham WT, Roden RL, Port JD, Gilbert EM, et al. Downregulation of a-and upregu-lation of /3-myosin heavy chain in intact, failing human ventricles. J Am Coll Cardiol 1997; February: 422A.
44. Lowes BD, Minobe WA, Abraham WT, Roden RL, Port JD, Gilbert EM, et al. Downregulation of a- and upregu-lation of /3-myosin heavy chain in intact, failing human ventricles. J Am Coll Cardiol 1997; 29: 422A.
45. Mereadier JJ, Lompre AM, Due P. Boheler KR, Fraysse JB, Wisnewsky C, et al. Altered sareoplasmie retieulum Ca-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990; 85: 305 – 309.
46. Hasenfuss G, Reineeke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sareoplasmie retieulum Ca2± ATPase in failing and nonfailing human myocardium. Cire Res 1994; 75: 434 – 442.
47. Gwathmey JK, Copelas L, Mackinnon R, Schoen F, Feldman M, Grossman W, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Cire Res 1987; 61: 70 – 76.
48. Raynolds MV, Bush EW, Taft CS, Roden RA, Bristow MR. Altered gene expression of several rate limiting enzymes in fatty acid oxidation and glyeolysis in the failing human heart. Circulation 1994; 90: 1 – 209.
49. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, et al. 31P magnetic resonance spectro-scopy in dilated eardiomyopathy and coronary artery disease; altered cardiac high-energy phosphate metabo-lism in heart failure. Circulation 1992; 86: 1810 - 1818.
50. Bristow MR, Abraham WT. Anti-adrenergie effects of angiotensin converting enzyme inhibitors. Eur Heart J 1995; 16: 37 – 41.
51. White M, Roden R, Minobe W, Khan MF, Larrabee P. Wollmering M, et al. Age-related changes in 13-adrenergie neuroeffeetor systems in the human heart. Circulation 1994; 90: 1225 – 1238.
52. Bristow MR, Hershberger RE, Port JD, Rasmussen R. /31 and /32 adrenergie receptor mediated adenylate eyelase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm 1989; 35: 295 – 303.
53. Gauthier C, Tavernier G, Charpentier F, Langin D, LeMaree H. Functional /33-adrenoceptor in the human heart. J Clin Invest 1996; 98: 556 – 562.
54. Bohm M, Diet F, Feiler G, Kemkes B, Erdmann E. a-adrenoeeptors and a-adrenoceptor-medicated positive inotropie effects in failing human myocardium. J Cardiovase Pharmaeol 1988; 12: 357 – 364.
55. Moravec CS, Schluchter MD, Paranandi L, Czerska B, Stewart RW, Rosenkranz E, et al. Inotropie effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990; 82: 1973 – 1984.
56. Holubarseh C, Hasenfuss G, Schmidt-Schweda S, Knorr A, Pieske B, Ruf T, et al. Angiotensin I and II exert inotropie effects in atrial but not in ventricular human myocardium: an in vitro study under physiological experimental conditions. Circulation 1993; 88: 1228 – 1237.
57. Iversen LL. Uptake processes for biogenie amines. Handbook of Psychopharmacology 1975; 3: 381 – 442.
58. Bristow MR. Changes in myocardial and vascular receptors in heart failure. JACC 1993; 22(Suppl A): 61 A–71A.
59. Pende A, Mitehusson KD, DeMaria CT, Blaxall BC, Minobe WA, Sherman JS, et al. Regulation of the mRNA-binding protein AUF1 by activation of the 13-adrenergie receptor signal transduction pathway. J Biol Chem 1996; 271: 8493 – 8501.
60. Blaxall BC, Pende A, Brewer G, Port JD. Differential affinities of the mRNA binding protein, AUF1, for 13-adrenergie receptor mRNAs. Cold Spring Harbor Symposium on Translational Control, 1996: 125.
61. Kennedy B, Ziegler MG. Cardiac epinephrine synthesis: regulation by a glueocorticoid. Circulation 1991; 84: 891 – 895.
62. Kaye DM, Cox H, Lambert G, Jennings GL, Turner A, Esler MD. Regional epinephrine kinetics in severe heart failure: evidence for extra-adrenal, non-neural release. Am J Physiol 1995; 269: H182–H188.
63. Freedman NJ, Liggett SB, Draehman DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human /31-adrenergie receptor. J Biol Chem 1995; 270: 17953 – 17961.
64. Roth NS, Campbell PT, Caron MG, Lefkowitz RJ, Lohse MJ. Comparative rates of desensitization of 13-adrenergie receptors by the /3-adrenergie receptor kinase and the cyclic AMP-dependent protein kinase. Proe Natl Aead Sei USA 1991; 88: 6201 – 6204.
65. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, et al. Increase of the Mr 40,000 pertussis toxin substrate in the failing human heart. J Clin Invest 1988; 82: 189 – 197.
66. Neumann J, Schmitz W, Scholz H, Meyerniek LV, Doring V, Kalma P. Increase in myocardial G, proteins in heart failure. Lancet 1988; ii: 936 – 937.
67. Bohm M, Esehenhagen T, Giersehik P. Lariseh K, Lensehe H, Mende U, et al. Radioimmunochemical quantification of G, in right and left ventricles from patients with ischwmic and dilated eardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 1994; 26: 133 – 149.
68. Baler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. New Engl J Med 1972; 284: 1209 – 1214.
69. McLeod AA, Brown JE, Kuhn C, Kitchell BB, Sedor FA, Williams RS, et al. Differentiation of hemody-namic, humoral and metabolic responses to 131- and 162-adrenergie stimulation in man using atenolol and propranolol. Circulation 1983; 67: 1076 – 1084.
70. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KB, Roden RL, et al. Selective down-regulation of the angiotensin II ATi receptor subtype in failing human left ventricular myocardium. Circulation 1997; 95: 1193 – 1200.
71. Haywood GA, Gullestad L, Katsuya T, Hutchinson 111-1, Pratt RE, Horiuehi M, et al. ATi and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95: 1201 – 1206.
72. Vago T, Bevilaequa M, Norbiato G, Baldi G, Chebat E, Bertora P. et al. Identification of aradrenergie receptors on sareolemma from normal subjects and patients with idiopathic dilated eardiomyopathy: characteristics and linkage to GTP-binding protein. Cire Res 1989; 64: 474 – 481.
73. Bristow MR, Port JD, Gilbert EM. The role of receptor regulation in the treatment of heart failure. Cardiovas-cular Drugs and Therapy 1989; 3: 971 – 978.
74. Colucci WS, Denniss AR, Leatherman GF, Quigg RJ, Ludmer PL, Marsh JD, et al. Intraeoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest 1988; 81: 1103 – 1110.
75. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Circulation 1989; 80: 314 – 323.
76. Milano CA, Allen LF, Rodman HA, Dolber PC, McMinn TR, Chien KR, et al. Enhanced myocardial function in transgenic mice overexpressing the 132-adrenergic receptor. Science 1994; 264: 582 – 586.
77. Geng Y-J, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, et al. Overexpression of Gsa accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice. Circulation 1996; 94 (Suppl 1): 1282.
78. Henegar JR, Brower GL, Kabour A, Janicki JS. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol 1995; 269: H1564—H1569.
79. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al for the Bucindolol Investigators. Dose-response of chronic # blocker treat-ment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89: 1632 – 1642.
80. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807 – 2816.
81. Gilbert EM, Abraham WT, Olsen S, Battler B, White M, Mealy P, et al. Comparative hemodynamic, left ventric-ular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817 – 2825.
82. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765– 1773.
83. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441 – 1446.
84. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349 – 1355.
85. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995; 75: 1220 – 1223.